BUCHANG PHARMA(SH:603858) Cai Jing Wang·2026-01-12 04:08Core Viewpoint - Shandong Buchang Pharmaceutical Co., Ltd. has signed an exclusive supply agreement with MEDISPEC (M) SDN BHD for the registration, promotion, distribution, and sales of injectable Efparepoetin alfa in a designated region, marking a significant step in expanding its product offerings in the biopharmaceutical market [1]. Group 1 - The agreement allows Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., a subsidiary of Buchang Pharmaceutical, to authorize MEDISPEC as the exclusive agent for the specified region [1]. - Injectable Efparepoetin alfa is a recombinant fusion protein composed of erythropoietin (EPO) and human immunoglobulin G2 (IgG2) Fc fragment, and it currently has no similar products approved for sale in China [1]. - The financial details of the transaction, including the transaction amount and key financial data of the counterparty, are considered commercial secrets and are exempt from disclosure under relevant regulations [1].